France's Eurofins H1 revenue up 2.5% on investment in laboratory network
France's Eurofins H1 revenue up 2.5% on investment in laboratory network
Overview
France laboratory testing firm's H1 revenue rose 2.5% year-on-year to €3.7 bln
Adjusted EBITDA margin for H1 expanded 130bps to 23.7%
Basic EPS for H1 grew 29% to €1.55, driven by operational improvements
Outlook
Eurofins targets mid-single-digit organic growth for FY 2026
Company expects adjusted EBITDA margin above FY 2025 level of 22.5% in 2026
Eurofins confirms FY 2027 adjusted EBITDA margin objective of 24%
Result Drivers
OPERATIONAL EFFICIENCIES - Margin expansion was driven by productivity gains, cost discipline, and closure of less profitable operations
INVESTMENT PROGRAMME BENEFITS - Ongoing investment in laboratory network and digitalisation supported operational improvements and profitability
STRONG CASH GENERATION - Higher cash conversion reflected lower capital expenditure and continued working capital discipline
Company press release: ID:nBw8SSs8da
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
H1 Adjusted Revenue |
| EUR 3.46 bln |
|
H1 Adjusted Net Income |
| EUR 395 mln |
|
H1 Adjusted EBITDA |
| EUR 877 mln |
|
H1 Adjusted EBITDA Margin |
| 23.7% |
|
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 6 "strong buy" or "buy", 7 "hold" and 3 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Eurofins Scientific SE is €67.25, about 4.7% below its July 22 closing price of €70.58
The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 16 three months ago
Reuters Recommended Reads
July 23 - France's Sartorius Stedim Biotech H1 revenue rises on recurring consumables
July 22 - Lonza lifts margin target, repeats latter half of 2026 to be slower
July 21 - Danaher Q2 revenue, adjusted EPS beats on life sciences segment strength; raises outlook
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Recent news on Eurofins Scientific SE
See all newsEurope Research Roundup: Avio, Genmab, Veolia
Europe Research Roundup: Avio, Genmab, Kerry Group
Brief: Eurofins 9M Revenues €5.61 Bln
European life sciences stocks rise on strong sector momentum
Brief: Eurofins Completes The Acquisition Of Element Materials Technology’S Life Sciences Testing Services Business